(Page 2 of 2)
the promise of TLR9 agonists. In 2007, a TLR9 drug being developed by former Idera rival Coley Pharmaceuticals and Pfizer performed poorly in a trial, causing Coley’s shares to tank. Pfizer bought the company later that year for $164 million.
Then, in 2009, Novartis pulled out of a deal with Idera to develop a TLR9 drug to treat respiratory diseases. Idera regained the rights to the drug, but the development program is on hold.
Agrawal refuses to lose hope, though. He points out that no safety concerns were observed in other Idera/Merck KGaA trials, in which IMO-2055 was tested in combination with other targeted treatments, such as erlotinib (Tarceva) and bevacizumab (Avastin). Merck KGaA is completing a Phase 2 trial of IMO-2055 plus cetuximab in head and neck cancer, with the data expected in the middle of next year. At that point, Agrawal says, “We will evaluate our best options for developing it going forward.” In the meantime, he adds, Merck KGaA will continue to investigate other TLR9 agonists that the companies generated under the collaboration.
And Idera is moving ahead with another TLR9 agonist called IMO-2125, which is being tested in hepatitis C patients. The company has completed Phase 1 trials and is waiting for data from early toxicology tests before it starts the next round of trials. Agrawal says Idera will pursue a combination strategy with this drug, as well, and its scientists are now evaluating whether they should consider testing it with newly approved protease inhibitors, such as Vertex’s telaprevir (Incivek).
Idera is also gearing up for Phase 2 tests of its first toll-like receptor antagonist, IMO-3100, which it is examining in autoimmune diseases such as lupus, rheumatoid arthritis, and psoriasis. The company has not yet determined which disease it will pursue, but it has set up a scientific advisory board to help determine the best clinical-development path.
Idera does have another Big Pharma partner on board—Whitehouse Station, NJ-based Merck, which is examining the use of toll-like receptor agonists in vaccines designed to treat cancer, infectious diseases, and Alzheimer’s disease.
Despite the pullback by the other Merck, Agrawal says, Idera has the resources to keep its development plans alive. “We have $28 million in cash on hand, no debt, and multiple assets,” he says. “We’re going to continue to invest our resources in expanding our clinical pipeline.”